Good morning,
We have eleven deals this week. Let's dive straight in.
In today's free edition:
🇩🇰 AEW selling Sydmarken campus in Copenhagen for a reported €65 million
🇮🇪 AstraZeneca opens $360 million facility in Dublin
🔒 For paying members only:
🇧🇪 University of Antwerp completes Vaccinopolis vaccine research centre
🇩🇪 Swiss Life Asset Managers acquires Salutem Praxisklinik in Mannheim
🇬🇧 First tenant at new Chesterford Research Park building
🇦🇹 Boehringer Ingelheim and Medical University of Graz open research laboratory
🇪🇸 Reiwa Healthcare takes space at SID campus in Madrid
🇮🇪 Planning sought for €10 million medical centre in Wexford
🇬🇧 Wild Bioscience expands at Milton Park following £45 million Series A
🇩🇪 Gateway Factory opens shared laboratory at BioCampus Cologne
🇦🇹 Carl Labs enters insolvency in Vienna
Subscribe here to unlock.
Enjoy today's newsletter,
— Stephen Ryan
AEW selling Sydmarken campus in Copenhagen's Medicon Valley
AEW is selling Sydmarken 5, a fully let asset in Copenhagen's Medicon Valley life sciences cluster, for around €65 million according to market reports.
The Sydmarken life science campus totals 32,755 sq m (352,570 sq ft) of space, including specialist laboratories and modern offices.
The main occupiers on the campus include Zealand Pharma and Ferrosan Medical Devices.
Cushman & Wakefield is advising on the deal, which is at first-round bid stage.
AEW bought the asset on behalf of the open-ended Eurocore fund in 2021.
In addition to this newsletter, we deliver bespoke research and strategic analysis for investors and developers, from acquisition support to market mapping and custom reporting. Hit reply to discuss your next project.
AstraZeneca opens $360 million facility in Dublin
AstraZeneca has officially opened a new active pharmaceutical ingredient (API) manufacturing facility in Dublin in the presence of Taoiseach Micheál Martin.
The plant is located on the company's 16.6-hectare Alexion Campus at College Business and Technology Park, Blanchardstown, and was first announced in 2021 as an investment of approximately $360 million to expand late-stage development and early-commercial small-molecule API capacity.
The facility integrates advanced automation, AI-driven process control and continuous-flow processing and is expected to create around 100 jobs over the next two years.
👇 As a free member, you're seeing only 2 of 11 deals this week. Subscribers see them all — why not take a 14-day trial?
